Answers are grounded in this paper and cite their sources.
Retrospective cohort study identifies factors linked to severe outcomes in older adults hospitalized with RSV, suggesting high-risk groups for vaccine prioritization.
Objectives We describe the burden of respiratory syncytial virus (RSV)-related hospitalization among community-dwelling older adults in the pre-vaccine era and identify factors associated with adverse hospital outcomes. Methods We conducted a population-based retrospective cohort study among adults aged ≥50 years hospitalized with RSV, using linked laboratory and health administrative data in Ontario, Canada during 2017-2020. We used modified Poisson regression models to assess associations between 25 individual factors and four hospital-related outcomes (30-day mortality, intensive care unit [ICU] utilization, hospital length of stay [LOS], and 30-day readmission). Results Of 3,221 adults hospitalized with RSV, 314 (9.7%) died within 30 days, 560 (17.4%) required ICU care , and the median (interquartile range) LOS was 6 (3-11) days. Of 2,913 adults discharged alive, 343 (11.8%) were readmitted within 30 days. Frailty strongly predicted all outcomes: mortality (adjusted risk ratio [aRR]=1.36; 95%CI, 1.05–1.76), ICU (aRR=1.45; 95%CI, 1.22–1.73), LOS (adjusted incidence rate ratio [IRR]=1.96; 95%CI, 1.81–2.12), and readmission (aRR=1.46; 95%CI, 1.14–1.87). Adults aged ≥90 years (aRR=2.37; 95%CI, 1.32–4.24), those with active cancer (aRR=1.63; 95%CI, 1.17–2.27) or other immunodeficiencies (aRR=1.54; 95%CI, 1.21–1.95), and chronic home care recipients (aRR=1.32; 95%CI, 1.03–1.67) had a higher risk of mortality, with similar trends observed for readmission. Conclusions RSV causes substantial morbidity and mortality among hospitalized older adults. These findings help identify high-risk groups for vaccine prioritization.
No takes yet. Share an insight, caveat, or question.
Atukorale et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: